Utilization of Intravenous Ribavirin Among Reproductive Age Adults in 2010-2017: A Population-Based Study in the Yinzhou District, Ningbo City of China.
Utilization of Intravenous Ribavirin Among Reproductive Age Adults in 2010-2017: A Population-Based Study in the Yinzhou District, Ningbo City of China.
复制标题
DOI：
10.3389/fpubh.2021.678785
复制
发表时间：
2021
影响因子：
5.2
通讯作者：
Zhan S
中科院分区：
文献类型：
--
作者：
Li H;Zhao H;Lin H;Shen P;Liu C;Zhan S
背景：静脉注射（IV）利巴韦林未在美国和欧盟获得批准，但在中国获得批准。几乎所有动物研究都发现利巴韦林具有显着的致畸和杀胚胎作用，因此调查育龄人群中静脉注射利巴韦林的使用流行率和趋势至关重要。目的：评估2010-2017年育龄人群静脉注射利巴韦林的使用流行率和趋势。方法：我们的研究设计是基于医疗保健数据库的回顾性横断面研究。我们利用鄞州医疗信息数据库识别并提取了2018年1月21日18-44岁居民的数据。通过2010年至2017年3家综合医院和24个社区卫生服务中心的门诊处方记录识别出静脉注射利巴韦林使用者队列。我们按性别、年龄、婚姻状况、文化程度、职业、医院级别、历年分层报告了静脉注射利巴韦林暴露的数量、比例和患病率，诊断和剂量。进一步分析和描述静脉注射利巴韦林使用的总体趋势，以及不同级别医院和常见诊断的趋势。结果：研究期间，育龄成人静脉注射利巴韦林的患病率为 6.02% (48,287/801,667)。 40-44岁成年人（8.04%，95% CI：7.90-8.17）、未婚患者（8.91%，95% CI：8.74-9.08）和受过9年以上教育（6.82%，95% CI：6.74-6.90）的患病率相对较高。与二级和三级医院相比，基层医院更有可能配发静脉注射利巴韦林（19.44%，95% CI：19.28-19.61）。最常见的诊断是急性上呼吸道感染 (AURI)，占静脉注射利巴韦林患者的 80%。对于 AURI 患者，静脉注射利巴韦林的患病率接近 30%。总体而言，静脉注射利巴韦林的使用率从2010年的1.72%下降到2017年的0.24%。结论：我们发现静脉注射利巴韦林主要用于AURI，这表明大量静脉注射利巴韦林可能是不合适的。在过去 8 年里，该病的患病率下降了 87%，我们鼓励临床医生和药剂师不断避免不当使用静脉注射利巴韦林。
Background: Intravenous (IV) ribavirin is not approved in US and European Union, but it is authorized in China. Significant teratogenic and embryocidal effects of ribavirin have been found in almost all animal studies, it is critical to investigate the prevalence and trends of the utilization of IV ribavirin among reproductive age population. Objective: To evaluate the prevalence and trends of IV ribavirin use among reproductive-age population in 2010–2017. Methods: The study design of our study is retrospective cross-sectional study based on healthcare database. We identified and extracted the data of residents aged 18–44 years by using Yinzhou healthcare information database at 21 January, 2018. A cohort of IV ribavirin users were identified through outpatient prescription records in 3 general hospitals and 24 community health centers from 2010 to 2017. We reported the number, proportion, and prevalence of the exposure to IV ribavirin stratified by sex, age, marital status, education level, occupation, hospital level, calendar year, diagnosis, and dosage. The overall trends of IV ribavirin use, and the trends in different levels of hospital and common diagnoses were further analyzed and described. Result: During the study period, the prevalence of IV ribavirin use among reproductive-age adults was 6.02% (48,287/801,667). Relatively higher prevalence were found in adults aged 40–44 (8.04%, 95% CI: 7.90–8.17), unmarried patients (8.91%, 95% CI: 8.74–9.08), and who had more than 9 years of education (6.82%, 95% CI: 6.74–6.90). Compared to secondary and tertiary hospitals, IV ribavirin was more likely to be dispensed in primary hospitals (19.44%, 95% CI: 19.28–19.61). The most common diagnoses were acute upper respiratory infections (AURIs), accounting for 80% of the patients exposed to IV ribavirin. For patients with AURIs, the prevalence of IV ribavirin was nearly 30%. Overall, the prevalence of IV ribavirin use decreased from 1.72% in 2010 to 0.24% in 2017. Conclusion: We found IV ribavirin was mainly used for AURIs which suggested that a large amount of IV ribavirin use was probably inappropriate. The prevalence was decreasing by 87% over the past 8 years, and we encourage clinicians and pharmacists to continually avoid inappropriate use of IV ribavirin.
登录
查看更多内容
影响因子：
9.9
作者：
Ovbiagele, B;Saver, JL;Crouse, JR
通讯作者：
Crouse, JR
影响因子：
2.8
作者：
Song Y;Bian Y;Petzold M;Li L;Yin A
通讯作者：
Yin A
影响因子：
2.3
作者：
Avalos LA;Chen H;Yang C;Andrade SE;Cooper WO;Cheetham CT;Davis RL;Dublin S;Hammad TA;Kaplan S;Pawloski PA;Raebel MA;Scott PE;Smith DH;Toh S;Li DK
通讯作者：
Li DK
影响因子：
6.5
作者：
Desalu, Ibironke;Kushimo, Olusola;Akinlaja, Olufunke
通讯作者：
Akinlaja, Olufunke
影响因子：
8.8
作者：
Schaapveld, M;de Vries, EGE;Willemse, PHB
通讯作者：
Willemse, PHB